Gold has long been a safe haven stock. But as the market turned toward tech, precious metal stocks took a back seat…until now. Could the timing of gold’s next bull run be perfect right now?
Let’s look at things that have historically helped gold prices skyrocket in the past:
- Geopolitical stress
- Declining interest rates
- A weaker dollar
- Global economic slowdowns
- Big accumulation by billionaires investors
Open a newspaper or read any headlines right now and you’ll likely see that all four boxes get checked on this list right now. The cheery on this golden sundae is that none of these things can be remedied overnight. What that means is that the bull market for gold could just be getting started.
But timing is important and technical levels for gold are beginning to show an eerily similar trend that they haven’t truly shown in nearly a decade:
The last time gold prices were at these levels, the entire sector exploded! And it wasn’t just any breakout move. Gold prices ran to all-time highs on a bull market move that lasted for months. Are we looking at gold’s next bull run?
The key to scoring big with gold stocks is to be ready before the big move comes and to be in front of the right gold opportunities. And historically speaking, some of the biggest returns have come from the junior stocks:
Roxgold investors who played the last big gold boom saw shares skyrocket from $0.38 to nearly $2.30… 497%
Investors who bought shares of gold company New Gold Inc. prior to the big gold market move, saw the stock trade below C$1.50 and road a wave to highs of more than C$14… 1,167%
Victoria Gold Corp moved from just $0.11 to highs of $1.55 during the last gold rush… 1,309%
Guyana Goldfields traded under $0.70 just as the last gold rush hit, with early investors that could have ridden that momentum to highs of $11.79… 1,609%
Early buyers of Wesdome Gold saw the stock at levels UNDER C$0.50 and had a chance to ride that to highs of nearly $6… 1,722%
And there are countless other examples of just how massive a gold price breakout can be for junior gold stocks and one junior gold mining stock may be on the verge of striking a major payload!
Roscan Gold Corporation (ROS.V): The Next Canadian Gold Stock To Watch For 2019
Right now analysts are screaming from the rafters about gold stocks and it isn’t just because the fundamental economics are pointing at a move in the precious metal. The price of gold bullion has now cracked a new 5-year high! All of this could be creating the perfect storm for another big move for gold stocks.
RosCan Gold Corporation (ROS.V) has already positioned itself in one of the most prolific gold regions in the world. Specifically, RosCan is currently in the process of assembling a sizeable land package in the Birimian Rocks of West Mali, the most productive greenstone gold belts on the continent.
Birmian rocks are major sources of gold and it just so happens that Mali is one of the largest producers of gold in Africa as it stands today. When it comes to mining, it’s Location, Location, and Location.
And RosCan Gold Corporation (ROS.V) is in one of the hottest regions on the planet. Africa holds 40% of the world’s gold reserves. Ghana, Burkina Faso, and Mali produce nearly twice what South Africa did in 2018.
Growth In West Africa Has Been Explosive!
Over the last decade, West Africa’s Senegal Mali fault zone has become a hotbed for mining activity. The region generated $1.2 billion in 2015 alone. Some analysts also speculate that junior mining companies may benefit greatly from the considerable upside of properties located close to mines that are owned by some of the world’s largest mining companies .
There could be real opportunity for investors in the handful of junior companies that are sitting on interesting properties within close proximity to the assets of multibillion-dollar market cap companies.
RosCan Gold Corporation (ROS.V) has amassed a significant land package, encompassing 271km2, through option agreements to acquire 100%-owned permits in the prolific gold prospective Birimian rocks of west Mali. Roscan believes these are high potential properties, as they are located in an area of existing gold deposits and multi-million-ounce producers. This includes B2 Gold’s Fekola Mine, which lies in a contiguous property to the west of its Kandiole project.
Prolific Gold Discoveries Signal Opportunity
Some of the largest gold miners are now looking to West Africa for potential. Because the region is so rich in gold, heads are turning and that could mean opportunities for mergers and acquisitions.
RosCan Gold Corporation (ROS.V) may be on the verge of something big. RosCan’s initial compilation of technical information of the Kandiole Project identified several areas of immediate interest.
According to the company, an initial exploration program consisting of prospecting, mapping and sampling of the entire land position with the objective of identifying areas for more detailed exploration, including drilling.
In addition, a program of detailed soil and termite sampling was completed in specific areas of the Mankouke and Moussala North permits, considered, in the short term, to be the most prospective. The initial sampling program on the Kandiole Project identified 13 artisanal mining areas that returned rock grab samples of more than 0.5 g/t gold with local highs exceeding 10 g/t gold at Niala.
These newly identified mining sites have not been evaluated in the past and as such represents new evaluation opportunities for RosCan Gold Corporation (ROS.V).
Roscan Gold reported positive assay results from both its diamond drilling and air-core (AC) drilling programs at its Kandiole Project in Mali, West Africa. The drilling program was completed during April to July of 2019 and was designed to test both the north and south extensions of the Mankouke gold discovery zone and many other strong termite and soil, gold anomalies.
|In hole ACMan 19-167||5.86 g/t Au over 26.0 m (incl. 9.44 g/t Au over 10.0 m)|
|In hole ACMan 19-168||3.74 g/t Au over 30.0 m (incl. 6.73 g/t Au over 6.0 m)|
|In hole DDH 19-04||8.63 g/t Au over 10.0 m (incl. 11.48 g/t Au over 7.0 m)|
|In hole DDH 19-03||6.53 g/t Au over 5.0 m (incl. 10.09 g/t Au over 3.0 m)|
|In hole DDH 19-03||5.56 g/t Au over 3.0 m (incl. 7.14 g/t Au over 2.0 m)|
|In hole DDH 19-08||3.45 g/t Au over 10.0 m (incl. 6.76 g/t Au over 3.0 m)|
“We are continuing to show thatwe have an excellent new gold discovery at Mankouke that appears to have strike and depth continuity. Our land package has great potential and we are extremely encouraged by the hits we are seeing on the Mankouke permit.“Greg Isenor, President and CEO of Roscan Gold
The New “Gold Coast” Could Mean Big M&A Opportunities For Junior Miners
According to Mining Intelligence, West Africa’s mining development pipeline could have real longevity. Roughly 33% of all assets, regardless of the commodity are in the production or construction stages, 45% of all projects undergoing economic assessment studies, and a whopping 74% of all exploration projects are focused on gold.
This focus on gold in the exploration stage indicates that the importance of gold in West Africa’s mining sector could only increase in the future, as new projects will enter the production phase. Some of the bigger players already sniffing around in this space include:
- Teranga Gold, B2Gold (Mali), a company with a market cap of over $400 Million
- Iamgold (Burkina Faso, Mali), a company with a market cap of over $2 billion
- Endeavour Mining (Burkina Faso, Mali, Côte d’Ivoire), a company with a market cap of nearly $2.5 Billion
- Semafo (Côte d’Ivoire), a company with a market cap of over $1.5 Billion
And this is just naming a few…
To some extent, all mining companies are worth the value of the gold in the ground that they own. The problem is that as they mine that metal they need to replenish it or risk having no resources left.
The gold mining industry is set for a “wave of mergers and acquisitions” as smaller miners seek to consolidate to capitalize on higher prices, according to Polyus . Smaller companies may be able to prospect for new ore deposits but larger ones will tend to have a hard time discovering large enough deposits to make a difference. Hence you could see larger companies deciding to buy smaller ones.
The world’s largest gold companies have been busy acquiring rivals this year, with Barrick Gold buying Randgold Resources in January and Newmont Mining acquiring Goldcorp in April.
“There will be numerous stocks…that will be bought by big companies,” says Don Coxe chairman of Chicago-based financial firm Coxe Advisors.
With gold prices on the rise, larger gold companies could run into higher production costs simply based on the size of the company and its overhead. As is typical with most industries of scale, smaller companies could stand to reap the rewards of having strong asset classes and prime location while also holding lower operating costs. Western Africa could be presenting new opportunities especially considering the prices of gold right now and RosCan Gold Corporation (ROS.V) is positioning itself in some of the most prolific regions.
Billionaires Are Already Starting To Pour Money Into Gold Stocks
When it comes to gold and gold stocks, most novices will hear about big money flowing from “Main Street.” But this usually comes well after Wall Street hedge funds have already piled in. So it’s important to read between the lines and sniff out early institutional bulls.
In recent months, some of the most elite investors have turned to precious metals like gold as a part of their overall investment strategies. Whether you like Trump or not you’ll most likely agree on one thing: he’s thrown a wrench into the U.S. political climate. It remains to be seen what comes of that, but the president’s actions so far have some billionaires expecting his disruptive political influence to spill over into the investing world even more.
That “pile in” we talked about may have quietly, already begun. Billionaire hedge fund manager and DoubleLine Capital founder, Jeffrey Gundlach said in a recent interview , “I am certainly long gold… Gold and commodities broadly should benefit this year.”
But he’s not alone either. Legendary investor Paul Tudor Jones said that gold is his favorite trade for the next year or two , “I think one of the best trades is gonna be gold. If I had to pick my favorite [bet] for the next 12 to 24 months, it’d probably be gold.” The yellow metal “has everything going for it,” he said, adding that if it can reach $1,400 an ounce, it will push to $1,700 “rather quickly.”
Other hedge fund managers, including Ray Dalio, David Einhorn, and John Paulson, have also started building gold positions. If billionaires like these own gold, this could be the sign that retail investors have been waiting for. With all of them citing market uncertainty driven by global economics, gold could be starting to sound like a really good idea.
As financial unrest continues across the globe, currency valuations sinking and major support from some of the worlds foremost billionaires prompting a gold play, the writing could already be on the walls.
Is This Perfect Timing For Junior Gold Stocks – Charts Don’t Lie
One of the best-known indexes of small resource stocks in the world is the TSX Venture Exchange. It doesn’t take a technical wiz to see patterns on a chart or what’s happened each time this index has hit a certain level…here we are, Now:
What will happen next? Well, as we said above, it comes down to timing. Let’s take this one step further and look at the price of gold over the years:
The precious metal has seen a cyclical trend over the last 20 years. The first 10 years saw the last long term bull market for gold. As it stands today, the market has been in a downtrend for almost 10 years after. That means investors aren’t “gifted” with “golden opportunities” regularly and being that this could be nearing the end of the latest 10-year cycle, the timing might be playing a big role considering the economic environment!
Remember the last mini bull run during the broader 10-year uptrend? That started at the tail end of 2008 and didn’t stop until well into 2011. Junior metals stocks exploded. The examples mentioned earlier were only a handful and those percentage moves were in the thousands.
Will You Be Ready For The Next Gold Rush?
The picture is even clearer. The climate for a gold boom is heating up in a big way and all the ingredients are in place that could give big reasons to be watching junior gold stocks right now. RosCan Gold (ROS.V) has staked its claim in one of the most prolific gold regions in the world. They are in the same region as some of the largest gold miners in the industry.
These are “early days” in its exploration program. RosCan Gold Corporation (ROS.V) property position is not only on the prolific Siribaya Structure which hosts the Siribaya, Kabaya, Seko and Mankouke discoveries but also covers many other gold anomalies and several other structures. With a significant land position of 100%-owned permits in an area of producing mines, this junior miner may soon hit the radar of gold bulls!
Tepid global economic data continues to suggest a bullish case for gold. Non-farm jobs figures, China PMI and the business climate for countries like Germany could point to a slowing economy. This would help the stance on safe-haven stocks. Furthermore, if the Fed sticks to a plan that would involve more rate cuts, there could be even brighter days ahead for the yellow metal.
“Growth still remains weak globally and we have geopolitical tension between the US and Iran. Additionally, $1,400 is a pretty strong support level for gold. We are still in a rate easing cycle right now. Overall factors are still supportive of higher gold prices.”Howie Lee, an economist at OCBC Bank in Singapore, to Reuters
This isn’t a secret anymore. With continued global financial uncertainty, a push for further decentralization of currencies, and the clear demand by the world’s biggest billionaires to shift investment into gold, what better time is there to find the next “undiscovered” junior gold company poised for huge growth potential in one of the worlds biggest gold producing regions?
RosCan Gold Corporation (ROS.V) has assembled a team of management with decades of experience in gold. Some have even been part of major buyouts by some of the world’s largest gold companies. With the recent progress that the company has seen from its drilling program, the fervent demand for safe-haven investment, and the stampede of gold billionaire bulls flooding into the market right now, it may be time to start looking at junior gold stocks before the Main Street rush opens the floodgates.
Top 5 Reasons To Have RosCan Gold (ROS.V) On You Gold Stock List
1. RosCan Gold (ROS.V) is in the process of assembling a sizeable land package in the Birimian Rocks of West Mali, the most productive greenstone gold belts on the continent.
2. RosCan Gold (ROS.V) has assembled a team of management with decades of experience in gold. Some have even been part of major buyouts by some of the world’s largest gold companies.
3. The rising price of gold has billionaire investors bullish on junior gold stocks specifically
4. The 20-year gold trend could be signaling a new bull market for gold
5. Geopolitical unrest and slowing global economies could ensure a strong argument for a longer-term bull trend for gold prices.
3 Penny Stocks Looking To Change The Biotech Industry
The world of biotech investing can be tricky. That’s particularly true when it comes to small-cap stocks in the industry. These companies often have terrific science, but no profits and little revenue; if any at all. But biotech stocks can offer true potential for investors who know what to look for.
Perhaps the best strategy for gaining exposure to this space is to look at early-stage, small-cap biotechs. By doing so, you put yourself at the front-line for cutting edge, experimental companies that could one day hit it big. Given this, here are 3 small-cap biotechs working to evolve in the biotech industry.
GT Biopharma Inc. (GTBP)
One company making groundbreaking developments in the biotechnology field is GT Biopharma Inc. (GTBP). GT Biopharma Inc. is an immune-oncology biotech company determined to create new treatments for cancer. In order to do this, the company leverages its proprietary TriKE technology to develop its pipeline. As of now, GT Biopharma has 6 treatment plans undergoing the clinical trial process.
So, what exactly is this TriKE technology platform? TriKE is actually an acronym for tri-specific killer engagers that are made to target NK’s or natural killer and tumor cells. Once they target NK cells, it binds to the CD16 receptor which makes a longer and stronger response compared to current treatment methods.
One use of TriKE has been to develop a way to target the HIV-Env protein. The design to do this is known as HIV-TriKE. As a matter of fact, the company recently announced data that showed the effectiveness of HIV-TriKE. It was shown that it enhanced NK cell cytokine production and effectively killed infected targets with HIV-Env.
“We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease and is able to kill HIV in the reservoir.” Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy,” expressed Anthony Cataldo, CEO and Chairman of GE Biopharma.
Conatus Pharmaceuticals Inc. (CNAT)
This next biotechnology company is known as Conatus Pharmaceuticals Inc. (CNAT). This company’s focus is different compared to GT Biopharma. It aims to treat chronic diseases that have a large unmet need. Its lead product candidate CTS-2090, inhibits IL-1β which treats inflammatory diseases.
In terms of news releases, the company has been slightly lackluster over the last two months. However, in early August Conatus released its Q2 financials which showed some profitability promise in its income statement.
Revenues increased and expenses decreased in Q2 2019 compared to Q2 2018 which significantly reduced the company’s net loss by $3.8 million. One potential hindrance factor in the financials could be Conatus’ consistently declining free cash flow.
Nuvectra Corporation (NVTR)
To top things off, we have a neurostimulation company known as Nuvectra Corporation (NVTR). The company has a commercial product called Algovita Spinal Cord Stimulation which treats chronic pain of the trunk and limbs. In addition to this, Nuvectra is awaiting FDA pre-market approval for its Virtis Sacral Neuromodulation which treats chronic urinary retention and overstive bladders.
Compared to Conatus, Nuvectra has produced recent news that investors can sink their teeth into. First off, the company appointed Jennifer Kosharek as CFO around a month ago. This is a strong appointment thanks to her 15+ years of accounting experience and other leadership positions with Nuvectra.
Furthermore, the company recently submitted its supplementary chemical composition and biocompatibility data to the FDA to support Virtis’ pre-market approval.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma Inc. (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma Inc. (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma Inc. (GTBP). Full Disclaimer Click Here
Are These Biotech Names On Your October Watch List?
Over the past two decades, the biotech sector has been one of the best sectors to watch. If experts are to be believed, then it is likely to continue to be a hot sector for the foreseeable future. However, biotech stocks require research and that can help when it comes to making a list of biotech stocks.
Once that is done, the investor needs to track the companies closely. Then it’s easier to decide upon the best course of action. Here is a look at three biotechnology penny stocks this month.
Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)
If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.
David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.
“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”
Over the last week, shares of PMCB stock have jumped from $0.0319 to highs of $0.0367 on Friday.
Biotech Stocks To Watch: Hepion Pharmaceuticals (HEPA)
The next biotech stock to watch is Hepion Pharmaceuticals Inc (NASDAQ:HEPA). The company is involved in manufacturing medicines meant for liver conditions emanating from non-alcoholic reasons. The company announced that its research article has been published by the highly influential peer-reviewed journal, the Journal of Pharmacology and Experimental Therapeutics.
The paper in question is titled “A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.” The study shows that Hepion’s product CRV431 could well be a solution for treating chronic diseases of the liver. The paper also stated that the medicine is suited to address a range of therapeutic needs.
Once the news broke, the company’s stock started soaring and soared over 43% at $3.58, well off the session high of $5.59.
Biotech Stocks To Watch: Protalix Biotherapeutics (PLX)
The other biotech stock that broke out more this week is Protalix Biotherapeutics Inc (NYSE:PLX). The company released data from the BRIDGE Phase 3 clinical study of its product PRX-102 and the revelations have proven to be highly encouraging. Out of a total of 22 patients who had been enrolled for the study, the data was gleaned from 16 of them.
The patients in question had been treated with PRX-102 for 12 months. The medicine is meant for treating Fabry disease and it has been revealed that there was an improvement in the function of kidneys in the patients. The stock soared by as much as 75% on Thursday and should definitely be on the watch lists of most investors.
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here.
Stock Price Newsletter – October 18, 2019
Biotech ETF’s Just Hit New Highs: 3 Stocks To Watch
The biotech sector has a plethora of stocks though. Therefore, an investor needs to put in the necessary research. On that note, here is a look at three biotech stocks to watch as sector stocks enjoy a bull run in October.
In Case You Missed It: Sernova (SVA) (SEOVF) Finds C-Peptide In Phase I/II Fasting Patient
Sernova Corp. (SVA) (SEOVF) has detected enduring levels of C-peptide (measured up to 30 days and continuing), a biomarker of transplanted beta cell insulin production, in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes.
These Healthcare & Biotech Stocks Deserve Your Attention This Month
The positive results provided a break for the sector. Furthermore, healthcare stocks have risen by 5.7% this year. The entire index has seen a nearly 20 percent gain, according to The Wall Street Journal. With this in mind, healthcare and biotechnology stocks are in focus this month.
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Featured4 days ago
What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!
Biotechnology1 week ago
Biotech Stocks In Focus Amid New Wave Of Drug Delivery
Biotechnology2 weeks ago
Top Biotechnology Stocks To Watch This Quarter
Biotechnology1 week ago
3 Top Biotech Stocks To Monitor In October
Biotechnology3 days ago
Healthcare Stocks To Watch Amid Bullish Earnings
Biotechnology2 weeks ago
Top Biotechnology Stocks To Watch After Latest News
Biotechnology2 days ago
Biotech Stocks To As Sector ETF’s Climb Higher
Biotechnology1 week ago
Biotechnology Stocks Gaining Ground In October; What To Watch